STOCK TITAN

Monogram Technologies to Host Third Quarter 2024 Results Conference Call on Tuesday, November 19, 2024 at 4:30 p.m. Eastern Time

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences earnings

Monogram Technologies (NASDAQ:MGRM), an AI-driven robotics company focused on orthopedic surgery, has announced its upcoming Third Quarter 2024 earnings conference call scheduled for Tuesday, November 19, 2024, at 4:30 p.m. Eastern Time. CEO Ben Sexson and CFO Noel Knape will host the call to discuss financial results for the quarter ended September 30, 2024, and key milestones. A presentation will accompany the webcast, accessible through the company's investor relations website. The call will be available for replay until February 19, 2025.

Monogram Technologies (NASDAQ:MGRM), un azienda di robotica guidata dall'AI focalizzata sulla chirurgia ortopedica, ha annunciato la sua prossima convocazione per la conferenza sugli utili del terzo trimestre 2024 fissata per martedì 19 novembre 2024, alle 16:30 ora orientale. Il CEO Ben Sexson e il CFO Noel Knape ospiteranno la chiamata per discutere i risultati finanziari per il trimestre conclusosi il 30 settembre 2024 e traguardi chiave. Una presentazione accompagnerà il webcast, accessibile tramite il sito web delle relazioni con gli investitori dell'azienda. La chiamata sarà disponibile per la riproduzione fino al 19 febbraio 2025.

Monogram Technologies (NASDAQ:MGRM), una empresa de robótica impulsada por IA enfocada en la cirugía ortopédica, ha anunciado su próxima llamada de conferencia sobre resultados financieros del tercer trimestre de 2024 programada para el martes 19 de noviembre de 2024, a las 4:30 p.m. Hora del Este. El CEO Ben Sexson y el CFO Noel Knape serán los anfitriones de la llamada para discutir los resultados financieros del trimestre que finalizó el 30 de septiembre de 2024 y hitos clave. Se acompañará una presentación al webcast, que será accesible a través del sitio web de relaciones con inversores de la empresa. La llamada estará disponible para reproducción hasta el 19 de febrero de 2025.

모노그램 테크놀로지스 (NASDAQ:MGRM)는 AI 기반 로봇 회사로 정형외과 수술에 집중하고 있으며, 2024년 11월 19일 화요일 오후 4시 30분 동부 표준시에 예정된 2024년 3분기 실적 컨퍼런스 콜을 발표했습니다. CEO 벤 섹슨과 CFO 노엘 크네이프가 참석하여 2024년 9월 30일로 종료된 분기의 재무 결과와 주요 이정표에 대해 논의할 것입니다. 웹캐스트에는 회사의 투자자 관계 웹사이트를 통해 접근할 수 있는 발표가 동반됩니다. 이 통화는 2025년 2월 19일까지 replay 가능합니다.

Monogram Technologies (NASDAQ:MGRM), une entreprise de robotique alimentée par l'IA axée sur la chirurgie orthopédique, a annoncé sa prochaine conférence téléphonique sur les résultats financiers du troisième trimestre 2024 prévue pour le mardi 19 novembre 2024, à 16h30 heure de l'Est. Le PDG Ben Sexson et le CFO Noel Knape animeront l'appel pour discuter des résultats financiers du trimestre clos le 30 septembre 2024 et des jalons clés. Une présentation accompagnera le webinaire, accessible via le site web des relations avec les investisseurs de l'entreprise. L'appel sera disponible en répétition jusqu'au 19 février 2025.

Monogram Technologies (NASDAQ:MGRM), ein KI-gesteuertes Robotikunternehmen, das sich auf die orthopädische Chirurgie konzentriert, hat seinen Konferenzanruf zur Bekanntgabe der Ergebnisse des dritten Quartals 2024 angekündigt, der für Dienstag, den 19. November 2024, um 16:30 Uhr Eastern Time angesetzt ist. CEO Ben Sexson und CFO Noel Knape werden den Anruf moderieren, um die finanziellen Ergebnisse für das am 30. September 2024 endende Quartal und wichtige Meilensteine zu besprechen. Eine Präsentation wird den Webcast begleiten, der über die Investor-Relations-Website des Unternehmens zugänglich ist. Der Anruf wird bis zum 19. Februar 2025 zur Wiederholung verfügbar sein.

Positive
  • None.
Negative
  • None.

AUSTIN, TX / ACCESSWIRE / November 12, 2024 / Monogram Technologies Inc. (NASDAQ:MGRM) ("Monogram" or the "Company"), an AI-driven robotics company focused on improving human health with an initial focus on orthopedic surgery, will hold a conference call on Tuesday, November 19, 2024 at 4:30 p.m. Eastern Time in conjunction with its reported financial results for the third quarter ended September 30, 2024 and to discuss key milestones. A press release detailing these results will be issued prior to the call.

Monogram CEO Ben Sexson and CFO Noel Knape will host the conference call, followed by a question-and-answer session. The conference call will be accompanied by a presentation, which can be viewed during the webcast or accessed via the investor relations section of the Company's website here.

To access the call, please use the following information:

Date:

Tuesday, November 19, 2024

Time:

4:30 p.m. Eastern Time (1:30 p.m. Pacific Time)

Toll-free dial-in number:

1-877-407-9208

International dial-in number:

1-201-493-6784

Conference ID:

13749601

The conference call will be broadcast live and available for replay at https://viavid.webcasts.com/starthere.jsp?ei=1693340&tp_key=7ecb89475b and via the investor relations section of the Company's website here.

A replay of the webcast will be available after 8:30 p.m. Eastern Time through February 19, 2025.

Toll-free replay number:

1-844-512-2921

International replay number:

1-412-317-6671

Replay ID:

13749601

About Monogram Technologies Inc.

Monogram Technologies (NASDAQ:MGRM) is an AI-driven robotics company focused on improving human health, with an initial focus on orthopedic surgery. The Company is developing a product solution architecture to enable patient-optimized orthopedic implants at scale by combining 3D printing, advanced machine vision, AI and next-generation robotics.

Monograms mBôs precision robotic surgical system is designed to autonomously execute optimized paths for high-precision insertion of its FDA-cleared mPress press-fit implants. The goal is well balanced better-fitting bone sparing knee replacements. The Company initially intends to produce and market robotic surgical equipment and related software, orthopedic implants, tissue ablation tools, navigation consumables, and other miscellaneous instrumentation necessary for reconstructive joint replacement procedures. Other clinical and commercial applications for the mBôs with mVision navigation are also being explored.

Monogram has obtained FDA clearance for mPress implants and applied for 510(k) clearance for its robotic products. The Company is required to obtain FDA clearance before it can market its products. Monogram cannot estimate the timing or assure the ability to obtain such clearances.

The Company believes that its mBôs precision robotic surgical assistants, which combine AI and novel navigation methods (mVision), will enable more personalized knee implants for patients, resulting in well balanced better-fitting knee replacements with bone sparing implants. Monogram anticipates that there may be other clinical and commercial applications for its navigated mBôs precision robot and mVision navigation.

To learn more, visit monogramtechnologies.com.

Forward-Looking Statements

This press release may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Statements other than statements of historical facts included in this press release may constitute forward-looking statements and are not guarantees of future performance or results and involve a number of risks and uncertainties. For example, the Company's statement regarding the Company's proposed use of net proceeds is a forward-looking statement. Forward-looking statements, other than statements of historical fact, are highly likely to be affected by other unknowable future events and conditions, including elements of the future that are or are not under our control, and that the Company may or may not have considered; accordingly, such statements cannot be guarantees or assurances of any aspect of future performance. Actual developments and results are highly likely to vary materially from any forward-looking statements as a result of a number of factors, including those described in the prospectus and the Company's other filings with the SEC. The Company undertakes no duty to update any forward-looking statement made herein. All forward-looking statements speak only as of the date of this press release.

Investor Relations

Chris Tyson
Executive Vice President
MZ North America
Direct: 949-491-8235
MGRM@mzgroup.us

SOURCE: Monogram Technologies Inc.



View the original press release on accesswire.com

FAQ

When is Monogram Technologies (MGRM) Q3 2024 earnings call?

Monogram Technologies' Q3 2024 earnings conference call is scheduled for Tuesday, November 19, 2024, at 4:30 p.m. Eastern Time.

How can I access Monogram Technologies (MGRM) Q3 2024 earnings call?

You can access the call using the toll-free number 1-877-407-9208 (US) or international number 1-201-493-6784, with Conference ID: 13749601. The webcast will be available at https://viavid.webcasts.com.

Until when will Monogram Technologies (MGRM) Q3 2024 earnings call replay be available?

The earnings call replay will be available until February 19, 2025, through toll-free number 1-844-512-2921 or international number 1-412-317-6671, using Replay ID: 13749601.

Monogram Technologies Inc.

NASDAQ:MGRM

MGRM Rankings

MGRM Latest News

MGRM Stock Data

84.75M
22.28M
34.22%
3.85%
0.81%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States of America
BROOKLYN